Literature DB >> 16087940

Optimal therapy for unresectable stage III non-small-cell lung cancer.

Everett E Vokes.   

Abstract

Entities:  

Mesh:

Year:  2005        PMID: 16087940     DOI: 10.1200/JCO.2005.95.028

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Six minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation.

Authors:  Esther Dajczman; Rima Wardini; Goulnar Kasymjanova; David Préfontaine; Marc Alexander Baltzan; Norman Wolkove
Journal:  Can Respir J       Date:  2015 Jul-Aug       Impact factor: 2.409

2.  The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer.

Authors:  Li Wang; Candace R Correa; Lujun Zhao; James Hayman; Gregory P Kalemkerian; Susan Lyons; Kemp Cease; Dean Brenner; Feng-Ming Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-17       Impact factor: 7.038

Review 3.  [Radiotherapy, chemotherapy and target therapy for treatment of head and neck cancer : new developments].

Authors:  R Knecht
Journal:  HNO       Date:  2009-05       Impact factor: 1.284

4.  From Cisplatin-Containing Sequential Radiochemotherapy towards Concurrent Treatment for Patients with Inoperable Locoregional Non-Small Cell Lung Cancer: Still Unanswered Questions.

Authors:  C C E Koning; J S A Belderbos; A L J Uitterhoeve
Journal:  Chemother Res Pract       Date:  2010-12-28

5.  Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with Non-Small Cell Lung Cancer.

Authors:  Apollonia L J Uitterhoeve; Mia G J Koolen; Rob M van Os; Kees Koedooder; Marlou van de Kar; Bradley R Pieters; Caro C E Koning
Journal:  Radiat Oncol       Date:  2007-07-23       Impact factor: 3.481

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.